Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

25 May 2016 - 27 May 2016
06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016

Genome-Wide Analysis Pinpoints Cancer Cell Genes Linked to Metastasis and Chemotherapy Susceptibility

By BiotechDaily International staff writers
Posted on 02 May 2013
Print article
Cancer researchers used genome-wide analyses to investigate the link between gene expression and anticancer compound sensitivity and cancer cell invasion.

Investigators at Academia Sinica (Taipei, Taiwan, Republic of China) and the National Taiwan University College of Medicine (Taipei, Republic of China) utilized the [US] National Cancer Institute's (Bethesda, MD, USA) panel of 60 tumor cell lines to gain insights on the genetic mechanism of drug sensitivity and on the contributing molecular factors to invasion heterogeneity. The NCI-60 human tumor cell line anticancer drug screen was developed in the late 1980s as an in vitro drug-discovery tool intended to supplant the use of transplantable animal tumors in anticancer drug screening. This screening model was rapidly recognized as a rich source of information about the mechanisms of growth inhibition and tumor-cell kill.

In the current study, the investigators identified invasion-associated (IA) genes by correlating their invasion profiling data with the Affymetrix gene expression data on NCI-60. They then employed the recently released chemosensitivity data of 99 anticancer drugs of known mechanism to investigate the gene-drug correlation, focusing on the IA genes. Afterwards, they collected data from four independent drug-testing experiments to validate the findings on compound response prediction. Finally, they obtained published clinical and molecular data from two recent adjuvant chemotherapy cohorts, one on lung cancer and one on breast cancer, to test the performance of their gene signature for patient outcome prediction.

Results published in the April 16, 2013, online edition of the journal BMC Medicine identified 633 IA genes from the invasion-gene expression correlation study. For each of the 99 drugs, the investigators obtained a subset of IA genes whose expression levels correlated with drug-sensitivity profiles. They identified a set of eight genes (EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32, and NNMT) showing significant gene-drug correlation with paclitaxel, docetaxel, erlotinib, everolimus, and dasatinib. This eight-gene signature for chemosensitivity prediction was validated by a total of 107 independent drug tests on 78 tumor cell lines, most of which were outside of the NCI-60 panel.

The eight-gene signature predicted relapse-free survival for the lung and breast cancer patients and featured the cancer hallmark epidermal growth factor receptor (EGFR) and genes involved in cell adhesion, migration, invasion, tumor growth, and progression.

Senior author Dr. Ker-Chau Li, professor of statistical science at Academia Sinica, said, "Our study found eight genes which were involved in invasion, and the relative activation of these genes correlated to chemotherapy outcome, including the receptor for growth factor EGF. We also found that some invasion genes had unique patterns of expression that reflect the differential cell responses to each of the chemotherapy agents - five drugs (paclitaxel, docetaxel, erlotinib, everolimus, and dasatinib) had the greatest effect."

Contributing author Dr. Pan-Chyr Yang, professor of medicine at National Taiwan University, said, "The discovery of prognostic biomarkers for chemotherapy patients remains critical toward improving the efficacy of cancer treatment. The eight-gene signature obtained here may help choice of treatment as part of individualized cancer therapy and our method of gene discovery may be applicable in studying other cancers."

Related Links:

Academia Sinica
National Taiwan University College of Medicine
National Cancer Institute




Print article

Channels

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.